MedTech Acquisition (MTAC) Short Interest Ratio & Short Volume

Short interest is the volume of MedTech Acquisition shares that have been sold short but have not yet been covered or closed out. As of July 31st, traders have sold 2,900 shares of MTAC short. 0.25% of MedTech Acquisition's shares are currently sold short. Learn More on MedTech Acquisition's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.25% of MedTech Acquisition's floating shares are currently sold short.

MedTech Acquisition saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 2,900 shares, a decline of 19.4% from the previous total of 3,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

MedTech Acquisition currently has issued a total of 7,390,000 shares. Some of MedTech Acquisition's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. MedTech Acquisition currently has a public float of 1,140,000 shares.

0.25% of MedTech Acquisition's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to MedTech Acquisition: OpGen, Inc. (0.00%), Abeona Therapeutics Inc. (19.80%), Korro Bio, Inc. (22.77%), Canopy Growth Corporation (6.82%), Aldeyra Therapeutics, Inc. (9.77%), Larimar Therapeutics, Inc. (8.10%), Contineum Therapeutics, Inc. (3.96%), Mesa Laboratories, Inc. (7.63%), 4D Molecular Therapeutics, Inc. (10.18%), Altimmune, Inc. (31.73%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.34 billion), Occidental Petroleum Corporation ($2.88 billion), Coinbase Global, Inc. ($2.50 billion), Rivian Automotive, Inc. ($2.47 billion), Palantir Technologies Inc. ($2.37 billion), Royal Caribbean Cruises Ltd. ($2.33 billion), T. Rowe Price Group, Inc. ($2.29 billion), Tractor Supply Company ($1.59 billion), Upstart Holdings, Inc. ($1.58 billion), and Enphase Energy, Inc. ($1.52 billion). View all of the most shorted stocks.

Short selling MTAC is an investing strategy that aims to generate trading profit from MedTech Acquisition as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for MedTech Acquisition occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MTAC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MTAC, twice per month. The most recent reporting period available is July, 31 2023.